<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00144807</url>
  </required_header>
  <id_info>
    <org_study_id>LNH03-3B</org_study_id>
    <nct_id>NCT00144807</nct_id>
  </id_info>
  <brief_title>ACVBP Plus Rituximab in Patients Aged From 18 to 59 Years With High-risk Diffuse Large B-cell Lymphoma</brief_title>
  <official_title>Study of ACVBP Plus Rituximab in Previously Untreated Patients Aged From 18 to 59 Years With High Risk Diffuse Large B-cell Lymphoma (Age-adjusted IPI = 2-3)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lymphoma Study Association</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Lymphoma Study Association</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a multicentric trial evaluating the efficacy of R-ACVBP in patients aged 18 to
      59 years with high risk diffuse large B-cell lymphoma
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This phase II non randomized study is based on the results of the LNH 98-5, LNH 87-2, LNH
      93-3 and LNH 98-3B studies.

      To date, the ACVBP regimen is considered as the reference induction treatment of the GELA in
      patients with 2-3 adverse prognostic factors. Indeed neither NCVBP regimen (LNH87-2) nor
      ECVBP (LNH93-3) led to increase the complete remission rate. More recently, the addition of
      etoposide to doxorubicin and cyclophosphamide (LNH98-3B) did not enhanced the complete
      remission rate with more toxicity. In patients &lt; 60 years with 2-3 adverse prognostic factors
      the complete remission rate remained less than 65% in all these studies. Consequently,
      increasing the quality of response remains a major goal in this group of young patients with
      adverse prognostic factors.

      It has been shown that the addition of rituximab to CHOP regimen significantly improved the
      CR rate in elderly patients with previously untreated large B-cell lymphoma when compared
      with CHOP alone without additional toxicities. Moreover, event-free survival and overall
      survival were found to be longer in the R-CHOP group. The present trial will evaluate the
      response rate obtained after four cycles of ACVBP combined to rituximab (R-ACVBP) before high
      dose therapy consolidative treatment in this group of higher risk patients.

      The LNH87-2 study has shown that intensive consolidation treatment with autologous stem cell
      support was beneficial to high risk patients in good response after a full induction phase.
      The long-term results of this randomised study prompted us to consider high dose therapy as
      the best consolidative option for these patients.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2003</start_date>
  <completion_date type="Actual">April 2012</completion_date>
  <primary_completion_date type="Actual">September 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Complete remission rate (CR + CRu)</measure>
    <time_frame>12 weeks</time_frame>
    <description>4 cycles of ACVBP</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Event-free survival and overall survival of patients submitted to autologous transplant and of the entire study population</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">128</enrollment>
  <condition>Diffuse Large Cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>R-AC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>rituximab + doxorubicin + cyclophosphamide + autologous stem cell transplantation</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rituximab</intervention_name>
    <arm_group_label>R-AC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>doxorubicin</intervention_name>
    <arm_group_label>R-AC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
    <arm_group_label>R-AC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>autologous stem cell transplantation</intervention_name>
    <arm_group_label>R-AC</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Patient with histologically proven CD20+ diffuse large B-cell lymphoma (WHO
        classification).

        Age from 18 to 59 years, eligible for transplant. Patient not previously treated. Age
        adjusted IPI = 2 or 3 With a minimum life expectancy of 3 months Negative HIV, HBV and HCV
        serologies &lt; 4 weeks (except after vaccination). Having signed a written informed consent.

        Exclusion Criteria:

        Any history of treated or non-treated indolent lymphoma. However, patients not previously
        diagnosed and having a diffuse large B-cell lymphoma with some small cell infiltration in
        bone marrow or lymph node may be included.

        Central nervous system or meningeal involvement by lymphoma. Contra-indication to any drug
        contained in the chemotherapy regimens. Poor renal function (creatinin level &gt;150 mmol/l),
        poor hepatic function (total bilirubin level &gt;30 mmol/l, transaminases &gt;2.5 maximum normal
        level) unless these abnormalities are related to the lymphoma.

        Poor bone marrow reserve as defined by neutrophils &lt;1.5 G/l or platelets &lt;100 G/l, unless
        related to bone marrow infiltration.

        Any history of cancer during the last 5 years with the exception of non-melanoma skin
        tumors or stage 0 (in situ) cervical carcinoma.

        Any serious active disease (according to the investigator's decision). Treatment with any
        investigational drug within 30 days before planned first cycle of chemotherapy and during
        the study.

        Pregnant or lactating women Adult patient under tutelage.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>59 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Olivier Fitoussi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lymphoma Study Association</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Christian Gisselbrecht, MD</last_name>
    <role>Study Director</role>
    <affiliation>Lymphoma Study Association</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Corinne Haioun, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Lymphoma Study Association</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hervé Tilly, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Lymphoma Study Association</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Groupe d'Etude des Lymphomes de l'adulte</name>
      <address>
        <city>Mont-Godinne</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Polyclinique Bordeaux Nord</name>
      <address>
        <city>Bordeaux</city>
        <zip>33300</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Henri Mondor</name>
      <address>
        <city>Créteil</city>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hématologie CHU de Lille</name>
      <address>
        <city>Lille</city>
        <zip>59000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Léon Bérard</name>
      <address>
        <city>Lyon</city>
        <zip>69008</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint Louis</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hématologie Adultes - Hôpital Necker</name>
      <address>
        <city>Paris</city>
        <zip>75743</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service d'Hématologie - Centre Hospitalier Lyon-Sud</name>
      <address>
        <city>Pierre-Bénite cedex</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Robert Debré</name>
      <address>
        <city>Reims</city>
        <zip>51092</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Henri Becquerel</name>
      <address>
        <city>Rouen</city>
        <zip>76038</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hématologie CHU Purpan</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Schweirische Arbeitsgruppe fur klinische Krebsforschung</name>
      <address>
        <city>Lausanne</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
    <country>Switzerland</country>
  </location_countries>
  <link>
    <url>http://www.gela.org</url>
    <description>Official site of the Groupe d'Etudes des Lymphomes de l'Adulte (In french)</description>
  </link>
  <reference>
    <citation>Feugier P, Van Hoof A, Sebban C, Solal-Celigny P, Bouabdallah R, Fermé C, Christian B, Lepage E, Tilly H, Morschhauser F, Gaulard P, Salles G, Bosly A, Gisselbrecht C, Reyes F, Coiffier B. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol. 2005 Jun 20;23(18):4117-26. Epub 2005 May 2.</citation>
    <PMID>15867204</PMID>
  </reference>
  <reference>
    <citation>Haioun C, Lepage E, Gisselbrecht C, Salles G, Coiffier B, Brice P, Bosly A, Morel P, Nouvel C, Tilly H, Lederlin P, Sebban C, Brière J, Gaulard P, Reyes F. Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: final analysis of the prospective LNH87-2 protocol--a groupe d'Etude des lymphomes de l'Adulte study. J Clin Oncol. 2000 Aug;18(16):3025-30.</citation>
    <PMID>10944137</PMID>
  </reference>
  <reference>
    <citation>Tilly H, Lepage E, Coiffier B, Blanc M, Herbrecht R, Bosly A, Attal M, Fillet G, Guettier C, Molina TJ, Gisselbrecht C, Reyes F; Groupe d'Etude des Lymphomes de l'Adulte. Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma. Blood. 2003 Dec 15;102(13):4284-9. Epub 2003 Aug 14.</citation>
    <PMID>12920037</PMID>
  </reference>
  <verification_date>September 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 2, 2005</study_first_submitted>
  <study_first_submitted_qc>September 2, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 5, 2005</study_first_posted>
  <last_update_submitted>September 1, 2015</last_update_submitted>
  <last_update_submitted_qc>September 1, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 2, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>lymphoma, diffuse large B-cell</keyword>
  <keyword>rituximab</keyword>
  <keyword>chemotherapy</keyword>
  <keyword>autologous stem cell transplant</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

